Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario.
Lorena LoreficePaolo MellinoJessica FrauGiancarlo CogheGiuseppe FenuEleonora CoccoPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024)
OCR has been confirmed to be a highly efficacious option for patients with PP and RR MS, even proving to be a valid exit strategy for natalizumab.
Keyphrases